- Importance of incorporating novel, more efficient designs in Oncology drug development
- Master Protocols for more efficient early-stage development
- Selected Phase 3 Adaptive Designs that reduce costs/timeline and/or improve the probability of success
Head of Biometrics at MedSource, Zoran Antonijevic has held executive positions in Pharmaceutical Companies and CROs and has designed more than 100 clinical trials in numerous therapeutic areas, many of which included adaptive designs. Zoran is a long-time Chair and leader of the DIA Adaptive Design Scientific Working Group. He has authored numerous papers and scientific presentations and was the editor of books “Optimization of Pharmaceutical R&D Programs and Portfolios” and “Platform Trials in Drug Development”.